BankPlus Trust Department Purchases Shares of 26,224 AbbVie Inc. (NYSE:ABBV)

BankPlus Trust Department bought a new stake in shares of AbbVie Inc. (NYSE:ABBV - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 26,224 shares of the company's stock, valued at approximately $4,660,000. AbbVie makes up approximately 1.5% of BankPlus Trust Department's portfolio, making the stock its 8th biggest position.

A number of other hedge funds have also added to or reduced their stakes in the stock. Quartz Partners LLC lifted its stake in shares of AbbVie by 3.2% in the 4th quarter. Quartz Partners LLC now owns 8,716 shares of the company's stock valued at $1,549,000 after purchasing an additional 272 shares during the period. Edge Capital Group LLC raised its stake in AbbVie by 27.4% during the fourth quarter. Edge Capital Group LLC now owns 5,349 shares of the company's stock valued at $951,000 after buying an additional 1,151 shares during the last quarter. Crestwood Advisors Group LLC boosted its holdings in AbbVie by 2.1% in the fourth quarter. Crestwood Advisors Group LLC now owns 113,021 shares of the company's stock worth $20,084,000 after acquiring an additional 2,305 shares in the last quarter. IFP Advisors Inc grew its stake in shares of AbbVie by 12.9% in the fourth quarter. IFP Advisors Inc now owns 43,249 shares of the company's stock worth $7,685,000 after acquiring an additional 4,928 shares during the last quarter. Finally, RWC Asset Management LLP bought a new position in shares of AbbVie during the fourth quarter valued at $273,000. 70.23% of the stock is owned by hedge funds and other institutional investors.

AbbVie Stock Up 0.6 %

Shares of NYSE:ABBV opened at $202.03 on Monday. The company has a quick ratio of 0.54, a current ratio of 0.66 and a debt-to-equity ratio of 17.94. The business's 50 day moving average is $181.25 and its 200 day moving average is $186.41. The stock has a market cap of $356.65 billion, a P/E ratio of 84.18, a price-to-earnings-growth ratio of 1.61 and a beta of 0.58. AbbVie Inc. has a 52-week low of $153.58 and a 52-week high of $207.32.

AbbVie (NYSE:ABBV - Get Free Report) last issued its earnings results on Friday, January 31st. The company reported $2.16 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.98 by ($0.82). AbbVie had a return on equity of 296.28% and a net margin of 7.59%. During the same quarter in the prior year, the firm earned $2.79 EPS. Sell-side analysts predict that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, May 15th. Shareholders of record on Tuesday, April 15th will be given a dividend of $1.64 per share. The ex-dividend date is Tuesday, April 15th. This represents a $6.56 annualized dividend and a yield of 3.25%. AbbVie's dividend payout ratio (DPR) is presently 273.33%.

Insider Activity

In other news, SVP Kevin K. Buckbee sold 1,800 shares of AbbVie stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of $172.24, for a total value of $310,032.00. Following the transaction, the senior vice president now owns 6,983 shares of the company's stock, valued at $1,202,751.92. The trade was a 20.49 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 0.25% of the company's stock.

Analysts Set New Price Targets

A number of brokerages recently issued reports on ABBV. BMO Capital Markets upped their price target on shares of AbbVie from $208.00 to $215.00 and gave the stock an "outperform" rating in a research note on Monday, February 3rd. Guggenheim upped their price objective on AbbVie from $212.00 to $214.00 and gave the company a "buy" rating in a research report on Monday, February 3rd. Morgan Stanley lifted their target price on AbbVie from $224.00 to $239.00 and gave the stock an "overweight" rating in a report on Monday, February 3rd. Bank of America reaffirmed a "neutral" rating and set a $191.00 price target on shares of AbbVie in a report on Tuesday, December 10th. Finally, Piper Sandler Companies reaffirmed an "overweight" rating and issued a $220.00 target price on shares of AbbVie in a research report on Tuesday, December 17th. Five analysts have rated the stock with a hold rating, seventeen have issued a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, AbbVie currently has an average rating of "Moderate Buy" and a consensus target price of $208.35.

About AbbVie

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.